Lemaitre Vascular ( (LMAT) ) has released its Q2 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LeMaitre Vascular, Inc., a company specializing in vascular devices, implants, and services, operates within the medical device industry, focusing on solutions for peripheral vascular disease.
In its Q2 2025 financial report, LeMaitre Vascular announced a 15% increase in sales, reaching $64.2 million, alongside a 16% rise in earnings per diluted share to $0.60. The company also declared a quarterly dividend of $0.20 per share and provided updated guidance for the year.
Key drivers of the company’s growth included a 27% increase in catheter sales and a 19% rise in graft sales. Geographically, the EMEA region saw a 23% sales increase, while both the Americas and APAC regions experienced 12% growth. The gross margin improved to 70.0%, attributed to higher selling prices and manufacturing efficiencies. Operating income rose by 12% to $16.1 million, reflecting the company’s robust performance.
Looking ahead, LeMaitre Vascular’s management has increased its guidance for 2025, anticipating continued growth in both sales and profits. The company remains optimistic about its strategic initiatives and market expansion plans, aiming to sustain its upward trajectory in the coming quarters.